Epic Sciences, Inc. is a privately held company that is developing new diagnostics to improve and personalize the treatment and management of cancer. Epic was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic has partnered with pharmaceutical companies, major cancer centers, the National Cancer Institute (NCI) and the National Institutes of Health (NIH) to advance this technology and improve patient outcomes and cancer therapeutic development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/13/12 | $13,000,000 | Series B |
Domain Associates Pfizer Venture Investments Roche Venture Fund | undisclosed |
| 07/30/14 | $30,000,000 | Series C |
Arcus Ventures Domain Associates Pfizer Venture Investments Roche Venture Fund RusnanoMedInvest | undisclosed |
| 04/29/17 | $40,000,000 | Series D |
Altos Capital Partners Domain Associates Genomic Health Hermed Capital  Pagoda Investment Reach Tone Limited RMI Partners Sabby Capital Vi-Ventures | undisclosed |
| 06/02/22 | $43,000,000 | Series F |
Arsenal Capital Partners Blue Ox Healthcare Partners Deerfield Management Company, L.P. LabCorp | undisclosed |
| 04/14/23 | $24,000,000 | Series G |
Arsenal Capital Management Blue Ox Healthcare Partners Deerfield Management Company, L.P. Domain Ventures LabCorp | undisclosed |
